Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 7/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 9/20 | 0.52 |
| ▸ | JAK1 | P23458 | 8/20 | 0.52 |
| ▸ | JAK2 | O60674 | 7/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231895 | 0.86 | PTK2 (0.52) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL1232852 | 0.86 | PTK2 (0.52) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL12900861 | 0.86 | PTK2 (0.52) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL690995 | 0.83 | MAPK3 (0.56) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL1560826 | 0.83 | MAPK10 (0.56) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL12413615 | 0.81 | MAPK3 (0.68) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL12413721 | 0.81 | TYK2 (0.56) | MAPK10TYK2JAK1JAK2MAPK9 | |
| SCHEMBL1558483 | 0.80 | MAPK10 (0.58) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL12102951 | 0.79 | MAPK10 (0.74) | MAPK10PTK2TYK2JAK1JAK2 | |
| SCHEMBL2063944 | 0.75 | ULK1 (0.55) | MAPK10PTK2MAPK9MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | MAPK10 301/4885PTK2 1/4885TYK2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.